


**Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-8 (Canceled).

9. (Previously presented): A compound of formula (I):



wherein:

R<sup>1</sup> represents -C<sub>1-6</sub> alkyl substituted by 1, 2, or 3 halogen or cyano groups; -C<sub>0-4</sub> alkyl-C<sub>3-8</sub>cycloalkyl; -C<sub>2-4</sub> alkyl-oxy-C<sub>1-4</sub> alkyl; -C<sub>1-4</sub> alkyl-aryl, wherein said cycloalkyl or aryl groups of R<sup>1</sup> may be optionally substituted by 1, 2, or 3 groups selected from halogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, cyano, amino and trifluoromethyl;

R<sup>2</sup> represents hydrogen or C<sub>1-6</sub> alkyl;

m represents 1;

R<sup>3</sup> represents hydrogen, methyl or halogen;

R<sup>4</sup> and R<sup>5</sup> independently represent hydrogen or methyl;

n represents 1;

p represents 1 or 2;

A represents phenyl optionally substituted by a halogen, cyano, trifluoromethyl, or trifluoromethoxy group;

or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

10. (Previously presented): The compound according to claim 9, wherein: A is unsubstituted phenyl.

11. (Previously presented): A compound which is:  
8-(4-(4-Fluorobenzyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-Cyclopropylmethyl-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-(Cyclohexyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-Cyclopentyl-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-Cyclobutyl-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-Cyclopropyl-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-(2-methoxyethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-(2,2,2-Trifluoroethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;  
or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

12. (Previously presented): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 9 and a pharmaceutically acceptable carrier or excipient.

13. (Previously presented): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 11 and a pharmaceutically acceptable carrier or excipient.

14. (Previously presented): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 9 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.

15. (Previously presented): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 11 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.

16. (Previously presented): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.

17. (Previously presented): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.

18. (Previously presented): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.

19. (Previously presented): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.

20. (Currently amended): A method of treating Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.

21. (Previously presented): A method of treating Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.